BUCHANG PHARMA(SH:603858) 2 1 Shi Ji Jing Ji Bao Dao·2026-02-12 13:12Core Viewpoint - The company, Buchang Pharma, has successfully implemented a share repurchase plan, demonstrating its commitment to shareholder returns and confidence in long-term growth, while also achieving a turnaround in financial performance for 2025 [1][3][7]. Financial Performance - In 2025, Buchang Pharma is expected to achieve a net profit of approximately 320 million to 468 million yuan, marking a significant turnaround from previous losses [3]. - The company plans to reduce goodwill impairment provisions significantly, from 615 million to 693 million yuan compared to the previous year, contributing to improved profitability [3]. Share Repurchase and Dividends - The company has repurchased shares worth 118.54 million yuan, acquiring 6.8564 million shares, which is 0.65% of its total share capital, at prices between 16.75 yuan and 17.71 yuan, below the initial upper limit of 23.98 yuan [1]. - Since its listing, Buchang Pharma has distributed a total of 7.948 billion yuan in dividends and repurchased shares worth 1.744 billion yuan, reflecting its commitment to returning value to shareholders [1]. Strategic Development - Buchang Pharma focuses on major disease areas, particularly cardiovascular diseases, and has established a diverse portfolio that includes proprietary traditional Chinese medicine, chemical drugs, and medical devices [4][5]. - The company has over 170 products included in the national medical insurance catalog, with 73 being exclusive products, generating sales exceeding 10.3 billion yuan in the first three quarters of 2025 [4]. Innovation and R&D - The company has invested over 1.8 billion yuan in R&D over the past three years, with a growing focus on biopharmaceuticals and vaccines, and holds 468 valid patents with 213 products under development [6]. - Buchang Pharma employs a collaborative R&D model, partnering with various research institutions to enhance its innovation capabilities [6]. Social Responsibility - The company actively engages in social responsibility initiatives, including a long-term public welfare program that has provided free surgeries for children with congenital heart disease and has contributed nearly 33 billion yuan in taxes since its establishment [7]. - Buchang Pharma's commitment to social responsibility enhances its brand image and strengthens its position in commercial partnerships [7]. Industry Outlook - The Chinese traditional medicine industry is poised for growth due to favorable policies and industry upgrades, positioning Buchang Pharma as a leading player in the pharmaceutical sector [8].